BioNTech SE

ISIN US09075V1026

WKN A2PSR2

Market cap (in EUR)

19,774 m

Country

Germany

Sector

Healthcare

Dividend yield

0.00%

Overview

Quote

Description

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Show more Show less

Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Germany

Chart

Financials

Key metrics

Market capitalisation, EUR	19,774 m
EPS, EUR	-2.38
P/B ratio	1.1
P/E ratio	159.5
Dividend yield	0.00%

Income statement (2024)

Revenue, EUR	2,751 m
Net income, EUR	-665 m
Profit margin	-24.18%

What ETF is BioNTech SE in?

There are 8 ETFs which contain BioNTech SE. All of these ETFs are listed in the table below. The ETF with the largest weighting of BioNTech SE is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).

ETF	Weight	Investment focus	Fund size (in m EUR)
iShares STOXX Europe Equity Multifactor UCITS ETF EUR (Dist)	0.09%	Equity Europe Multi-Factor Strategy	151
L&G Gerd Kommer Multifactor Equity UCITS ETF USD Distributing	0.01%	Equity World Multi-Factor Strategy	139
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	0.91%	Equity United States Health Care Biotech	44
L&G Gerd Kommer Multifactor Equity UCITS ETF USD Accumulating	0.01%	Equity World Multi-Factor Strategy	755
L&G Global Equity UCITS ETF	0.01%	Equity World Social/Environmental	941
L&G Europe ex UK Equity UCITS ETF	0.10%	Equity Europe Social/Environmental	880
Amundi Prime Eurozone UCITS ETF DR (D)	0.15%	Equity Europe	56
Amundi Prime Europe UCITS ETF DR (D)	0.09%	Equity Europe	147

Performance

Returns overview

YTD	-23.60%
1 month	-8.10%
3 months	-13.73%
6 months	-13.93%
1 year	-26.32%
3 years	-47.89%
5 years	-16.35%
Since inception (MAX)	+564.37%
2024	+13.87%
2023	-33.67%
2022	-33.06%
2021	+195.14%

Monthly returns in a heat map

Risk

Risk metrics in this section:

Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.

ETF returns include dividend payments (if applicable).